Novel coronavirus (SARS‐CoV‐2) infection in a patient with multivisceral transplant.

More experience needs to be accumulated in order to conclude whether transplanted patients represent or not a group of risk for SARS-CoV-2 infection and determine the best way to handle immunosuppression treatment. Novel coronavirus (SARS-CoV-2) infection in a patient with multivisceral transplant To the Editor, Coronavirus disease 2019 (COVID-19) pandemic has become one of the most challenging episodes in the history of modern public health, with particular emphasis in high-risk population.1 However, the evidence regarding their response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for COVID-19 is scant.2 Herein, we present the clinical and therapeutic course of a SARS-CoV-2 infection in a patient with multivisceral transplant and a recent tuberculosis infection. [Extracted from the article]